While its advanced synthesis and integrated biologics platforms drove strong growth in 2025, the company’s specialized modalities sales declined versus the prior year.
The agreement is intended to accelerate an IND filing for Akari’s lead antibody-drug conjugate program targeting metastatic urothelial cancer by late 2026.
